RDIF brings together the best Russian
and international technologies in the fight
against COVID-19
Production of «Sputnik V», the first Russian COVID-19 vaccine

RDIF has agreed to organize joint production of a COVID-19 vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology. It is expected that the vaccine will be produced at two sites, with one being set up together with the R-Pharm Group in Yaroslavl, and the other with Sistema at the Alium plant in Zelenograd.
There are also plans to export products to the Middle East, Latin America and other countries.
«Sputnik V» vaccine was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus.

Production of antiviral drugs

RDIF and the ChemRar Group have launched the production of Avifavir - the first drug registered in Russia that has demonstrated effectiveness against COVID-19 in clinical trials.
Avifavir is one of the two registered COVID-19 drugs in the world and the first Favipiravir-based drug in the world approved for treatment of COVID-19.

Production of diagnostic tests for the detection of coronavirus

Jointly with Japan’s K.K. Mirai Genomics, RDIF has invested in the production and distribution of the Russian-Japanese diagnostic system EMG - Evotech-Mirai Genomics, which is one of the world’s most accurate and fastest systems for the detection of coronavirus. Results are achieved in just 30 minutes. The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund.

Diagnosis and detection of pneumonia

RDIF has launched a project to diagnose and detect pneumonia, including that caused by coronavirus, using CT scans combined with the Russian- UAE artificial intelligence (AI) technology developed jointly by Group 42 (G42), RDIF and Medscan Group.

Production of a drug for coronavirus therapy based on blood plasma

RDIF and Rostec partner announced a partnership with Nacimbio (part of the State Corporation Rostec) to carry out a joint project for the production of a drug for coronavirus therapy based on blood plasma. One of Nacimbio’s enterprises has developed a universal technology for the production of human immunoglobulins for intravenous administration. The BioGam drug produced using this technology has successfully passed the first phase of clinical trials. The partnership involves the production of an immunoglobulin preparation containing antibodies to the SARS CoV-2 coronavirus.